Fibrocell Science — Investor Presentation (January 2014)
31 slides from Fibrocell Science's investor presentation, Jan 13, 2014
Slide 1: Fibrocell Corporate Presentation
Exhibit 99.2 Fibrocell Corporate Presentation January 2014
Slide 2: Forward Looking Statement
Forward Looking Statement Thispresentationincludesstatementsthat are “forward-looking statements.”Forward-lookingstatements include, without limitation, our ability (i) to timely enroll, commence and successfully complete our clinical programs, (ii) to successfully genetically modify the fibroblast
Slide 3: Corporate Profile
Corporate Profile • NYSE MKT: FCSC • Market Cap: ~$190 million as of 1/9/2014 • Ownership: ~70% institutional, significant investment by Randal J. Kirk affiliates • HQ facility: Exton, PA • ~60 employees • Management Team– development, manufacturing and commercial experience David Pernock, Chairman
Slide 4: Investment Highlights
Investment Highlights • 2 clinical stage development sBLA programs: azficel-T to treat restrictive burn scarring and vocal cord scarring – Based on proprietary, autologous fibroblast platform technology – Phase II top-line results anticipated Q1 2015 • Strategic collaboration with Intrexon Corporati
Slide 5: Autologous Fibroblast Cells
Autologous Fibroblast Cells • Most common cells in connective tissue, which produce collagen and extracellular matrix proteins • Ideal delivery vehicle to treat skin and connective tissue diseases locally, not systemically, with genetically modified fibroblast cells 5
Slide 6: Fibrocell Leadership: Proprietary technology to address unmet needs
Fibrocell Leadership: Proprietary technology to address unmet needs • The scientific leader in autologous fibroblasts, the most common cells in connective tissue • Ideal to deliver genes to a localized area • Autologous cells eliminate risk of patient rejection • Unique expertise in collection and c
Slide 7: Strategic Focus: Leveraging the Potential of Our Autologous Fibroblast Platform
Strategic Focus: Leveraging the Potential of Our Autologous Fibroblast Platform • Restrictive Burn Scarring • Recessive Dystrophic • Vocal Cord Scarring Epidermolysis Bullosa (RDEB) • Morphea Scleroderma • Cutaneous Eosinophilic Fasciitis 7
Slide 8: NEW ECC: Tenascin-X Deficiency
NEW ECC: Tenascin-X Deficiency • NEW ECC with Intrexon signed January 10, 2014 • Tenascin-X is an extracellular matrix glycoprotein found in loose connective tissue • Believed that tenascin-X helps determine how collagen fibrils are deposited in the extracellular matrix of joints, organs, and skin,
Slide 9: Development Pipeline
Development Pipeline Indication 2H2013 1H2014 2H2014 1H2015 2H2015 1H2016 2H2016 RBS (azficel-T) Phase II Primary Endpoint Phase III BLA VCS (azficel-T) Phase II Primary Endpoint Phase III BLA RDEB –Orphan Product Optimization and PoC Studies; Pre-Clinical Phase I Phase II/III Morphea –Orphan Produc
Slide 10: Azficel-T Label Extension Opportunities
Azficel-T Label Extension Opportunities 10
Slide 11: Importance of BLA for azficel-T
Importance of BLA for azficel-T • Label Expansion higher – value opportunities near term – Not starting from scratch • 2 clinical stage development programs – Phase II Restrictive Burn Scarring – Phase II Vocal Cord Scarring • Demonstrated ability to manufacture autologous therapy across product can
Slide 12: Scarring: azficel-T Label Extensions
Scarring: azficel-T Label Extensions Fibrocell Scarring Pipeline: • Restrictive Burn Scarring (U.S. only) Addressable Market Opportunity - 40,000 hospitalized burn victims in 2012 (1) - Total excludes military burn injuries - Addressable Patient Population: - 25% treated(2) - Pool of patients availa
Slide 13: Restrictive Burn Scarring Overview
Restrictive Burn Scarring Overview • Opportunity is to treat mobility limitations created by burn scar tissue • Typically at the shoulder, elbow, wrist, knee • No FDA approved therapeutics, unmet medical need is significant • Current therapies include surgery option • 40,000 or more yearly hospitali
Slide 14: Restrictive Burn Scarring
Restrictive Burn Scarring Results from Open-Label Case Studies (1) Pre-Treatment 12 Mo Post-Treatment 14 Mo Post-Treatment • Full range-clench • Fine finger movement Six Months Post Treatment (2): • Full range of neck rotation, and pain free • Patient has stopped all analgesics • Discarded cervical
Slide 15: Restrictive Burn Scarring Phase II
Restrictive Burn Scarring Phase II • Double-blind, randomized, placebo-controlled, 21 subjects (up to 30) • Subjects inclusion criteria: – Unilateral restrictive burn scars of a jointed area – 20-60% restriction in normal range of motion • FDA Agreed-upon Validated Measurement Scales: 1 – Range of M
Slide 16: Vocal Cord Scarring Overview
Vocal Cord Scarring Overview • No FDA approved therapeutics • Most commonly encountered finding is loss of voice – Due to surgery, radiation therapy, vocal cord trauma and idiopathic causes – 200,000-700,000 current prevalence; treatment options include surgery, voice therapy • Positivepilot studyre
Slide 17: Vocal Cord Scarring Phase II
Vocal Cord Scarring Phase II • Trial initiated 2H 2013 • Double-blind, randomized, placebo-controlled, 20 subjects (up to 30) • 4 month efficacy endpoint: Top-line data expected Q1 2015 • Subject inclusion criteria: – Presence of unilateral or bilateral vocal fold scarring or age-related dysphonia –
Slide 18: Intrexon Collaboration
Intrexon Collaboration Incorporating Intrexon’s Synthetic Biology to Expand Fibrocell’s Fibroblast Platform 18
Slide 19: The Power of the Intrexon Collaboration
The Power of the Intrexon Collaboration Autologous Fibroblast Expertise Synthetic Biology Platform 19
Slide 20: Intrexon Collaboration Highlights
Intrexon Collaboration Highlights • Multiple orphan disease indications • Genetically-Modified (GM) autologous fibroblasts with therapeutic gene(s) of interest for the localized treatment of skin and connective tissue diseases (non- systemic),addressingthe underlyingcauseof thesediseasesandproviding
Slide 21: Intrexon RheoSwitch Therapeutic System: Key for Autoimmune Diseases
Intrexon RheoSwitch Therapeutic System®: Key for Autoimmune Diseases Intrexon Corp. proprietary on/off biologic switch, incorporated into an UltraVector® designed vector Three-component transcriptional regulator that provides inducible gene expression Maintains gene program in inactive state until p
Slide 22: Orphan Skin Diseases: Large Unmet Market Opportunities
Orphan Skin Diseases: Large Unmet Market Opportunities • Recessive Dystrophic Epidermolysis Bullosa (RDEB) • $560 million-$2.2 billion:(5,6,7,8) • Morphea Scleroderma • $300-$350 million:(3,4) • Cutaneous Eosinophilic Fasciitis • $120-$140 million:(1,2) References –See Appendix on Slide 28 22
Slide 23: RDEB: Unique Approach to Localized Treatment of Rare Skin Disease
RDEB: Unique Approach to Localized Treatment of Rare Skin Disease • RDEB characterized primarily by the formation of blisters over widespread areas of the body, resulting from a mutation in the COL7A1 gene which encodes for type VII collagenthe– main component of connective and fibrous tissues • A g
Slide 24: Autoimmune Skin Diseases – Localized Treatment
Autoimmune Skin Diseases – Localized Treatment • Rare and serious orphan autoimmune diseases that manifest on the skin – Morphea Scleroderma • Underlying cause is accumulation of collagen – Cutaneous Eosinophilic Fasciitis • Underlying cause of inflammation is accumulation of eosinophils • Treatment
Slide 25: Financials
BepeteeTCe Lt Financials \ as Vy a ee Wh: Wee” <f]
Slide 26: Financial Information
Financial Information • Cash position ~$64 million following October 2013 financing • $50.5 million gross proceeds from underwritten offering - Led by Barclays, co-managers Wedbush and Griffin • Quarterly average use of cash: $6-7 million • 39.8 million shares outstanding - 6.0 million warrants o/s;
Slide 27: 2014 Key Milestones
2014 Key Milestones Milestone Timing Restrictive Burn Scarring Q2 2014 • Phase II Enrollment Complete Vocal Cord Scarring Q2 2014 • Phase II Enrollment Complete RDEB End of 2014 • Proof of Concept & IND Completed Key Publications: • BMP2 2H 2014 • Genomic Stability • Skin-Derived Mesenchymal Skin Ce
Slide 28: 2015 Key Milestones
2015 Key Milestones Milestone Timing Restrictive Burn Scarring Q1 2015 • Phase II Top-line Results Vocal Cord Scarring Q1 2015 • Phase II Top-line Results RDEB 1H 2015 • Phase I Restrictive Burn Scarring 1H 2015 • Phase II Complete Vocal Cord Scarring 1H 2015 • Phase II Complete Morphea/Linear Scler
Slide 29: Key Scientific & Clinical Advisors
Key Scientific & Clinical Advisors Institution Focus MIT, David Koch Institute Professor; Harvard-MIT Division of Dr. Robert Langer Chief Scientific Advisor Health Sciences & Technology, Faculty UCLA, Associate Professor, Department of Head and Neck Dr. Dinish Chhetri Vocal Cord Scarring Surgery; UC
Slide 30: Investment Highlights
Investment Highlights • 2 clinical stage development sBLA programs: azficel-T to treat restrictive burn scarring and vocal cord scarring – Based on proprietary, autologous fibroblast platform technology – Phase II top-line results anticipated Q1 2015 • Strategic collaboration with Intrexon Corporati
Slide 31: Appendix – References
Appendix –References Slide 21 –Orphan Skin Diseases (1) Cutaneous eosinophilias represent a family of more than 30 different conditions ranging from eosinophilic cellulitissyndrome) (Wells’ to eosinophilic dermatosis and eosinophilic fasciitis. The prevalence varies based on which conditions are tar
Fibrocell Science — Investor Presentation (January 2014) on 6ix